P. Beswick

发表

BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells.

D. Riddell, C. Dingwall, Christopher N. Johnson, 2008, Bioorganic & medicinal chemistry letters.

Synthesis of an isomer of the oxaspirobicyclic tetronic acid unit of the CCK-B receptor antagonist tetronothiodin

P. Beswick, P. C. Page, H. Vahedi, 2003 .

What does the aromatic ring number mean for drug design?

Paul Beswick, S. Ward, P. Beswick, 2014, Expert opinion on drug discovery.

THE SYNTHESIS OF 3-METHYLENE-2,3-DIHYDROBENZOFURAN STABILIZED AS ITS TRICARBONYLCHROMIUM COMPLEX

P. Beswick, D. Widdowson, 1985 .

The Synthesis of 3-Methylene-2,3-dihydrobenzofuran Stabilised as its Tricarbonylchromium Complex

P. Beswick, D. Widdowson, 1985 .

Progress in the Discovery of Ca Channel Blockers for the Treatment of Pain

P. Beswick, 2017 .

African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase

S. Ward, J. Atack, Srinivasa P. S. Rao, 2017, European journal of medicinal chemistry.

Chapter 9 – The role of medicinal chemistry in the drug discovery process

P. Beswick, A. Naylor, 2013 .

Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.

S. Senger, P. Beswick, Robert J Gleave, 2010, Bioorganic & medicinal chemistry letters.

Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics

Dorothy Ko, P. Beswick, K. Valko, 2018, ADMET and DMPK.

Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; the identification of (2R)-2-pyrrolidinecarboxamidine as a potent and selective haem-co-ordinating inhibitor.

James M. Woolven, Richard Graham Knowles, S. Hodgson, 2011, Bioorganic & medicinal chemistry letters.

An Assay for Periplasm Entry Advances Development of Chimeric Peptide Antibiotics.

Rachel L. Dods, M. Dawson, P. Beswick, 2020, ACS infectious diseases.

Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain.

Andrew J. Brown, P. Beswick, Robert J Gleave, 2010, Bioorganic & medicinal chemistry letters.

2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.

Andrew J. Brown, P. Beswick, Robert J Gleave, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X(7) antagonists.

P. Beswick, Robert J Gleave, D. Walter, 2010, Bioorganic & medicinal chemistry letters.

A challenge finding P2X1 and P2X4 ligands

M. Lochner, A. J. Thompson, P. Beswick, 2019, Neuropharmacology.

Modulating AMPA Receptors for the Treatment of CNS Disorders

S. Ward, P. Beswick, Tristan Reuillon, 2017 .

AMPA Receptor Positive Allosteric Modulators: Potential for the Treatment of Neuropsychiatric and Neurological Disorders.

S. Ward, P. Beswick, Tristan Reuillon, 2016, Current topics in medicinal chemistry.

AMPA receptor-positive allosteric modulators for the treatment of schizophrenia: an overview of recent patent applications.

S. Ward, P. Beswick, Lewis E. Pennicott, 2015, Future medicinal chemistry.

Synthesis of an Isomer of the Oxaspirobicyclic Tetronic Acid Unit of the CCK‐B Receptor Antagonist Tetronothiodin.

P. Beswick, P. C. Page, H. Vahedi, 2003 .

Novel 1, 2, 4-oxadiazoles as potent and selective histamine H3 receptor antagonists

J. C. Barnes, J. Clapham, P. Beswick, 1996 .

The synthesis of 4 - Substituted Indoles via arenetricarbonylchromium(0) complexes

P. Beswick, D. Widdowson, G. Nechvatal, 1988 .

Chelation-controlled intermolecular hydroacylation: direct addition of alkyl aldehydes to functionalized alkenes.

M. Willis, P. Beswick, S. McNally, 2004, Angewandte Chemie.

Synthetic applications of lithiated tricarbonyl-η6-arenechromium(0) complexes: copper and palladium catalysed substitutions

P. Beswick, D. Widdowson, S. Leach, 1984 .

Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.

I. Chessell, A. Naylor, C. Bountra, 2004, Bioorganic & medicinal chemistry letters.

Novel 1,2,4-Oxadiazoles as Potent and Selective Histamine H3 Receptor Antagonists.

J. C. Barnes, J. Clapham, P. Beswick, 1996 .

The acid-mediated intramolecular 1,3-dipolar cycloaddition of derived 2-nitro-1,1-ethenediamines for the synthesis of novel fused bicyclic isoxazoles

P. Beswick, Robert J Gleave, S. Frydrych, 2010 .

The Cyclooxygenase-2 Inhibitor GW406381X [2-(4-Ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] Is Effective in Animal Models of Neuropathic Pain and Central Sensitization

S. Summerfield, I. Chessell, A. Naylor, 2005, Journal of Pharmacology and Experimental Therapeutics.

Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptor.

P. Beswick, Robert J Gleave, D. Walter, 2010, Bioorganic & medicinal chemistry letters.

Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors.

M. Gleeson, Irina S. Chuckowree, S. Ward, 2016, European journal of medicinal chemistry.

The role of the cylooxygenase pathway in nociception and pain.

I. Chessell, S. Bingham, D. Blum, 2006, Seminars in cell & developmental biology.

Characterisation of the specific binding of the histamine H3 receptor antagonist radioligand [3H]GR168320.

J. Barnes, Gavin Kilpatrick, C. O'shaughnessy, 1996, European Journal of Pharmacology.

Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides.

A. Bond, P. Beswick, S. Stanway, 2022, Bioconjugate chemistry.

Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer

P. Jeffrey, P. Beswick, Liuhong Chen, 2022, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor.

S. Senger, P. Beswick, E. Demont, 2010, Bioorganic & medicinal chemistry letters.

Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X(7) receptor.

S. Senger, P. Beswick, Robert J Gleave, 2010, Bioorganic & medicinal chemistry letters.

Structure-Guided Chemical Optimization of Bicyclic Peptide (Bicycle) Inhibitors of Angiotensin-Converting Enzyme 2.

G. A. Bezerra, M. Hyvönen, P. Beswick, 2023, Journal of medicinal chemistry.

Abstract C061: BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models

N. Keen, P. Jeffrey, M. Rigby, 2019 .

Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models

M. Koehler, N. Keen, P. Jeffrey, 2019, Experimental and Molecular Therapeutics.

Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.

I. Chessell, C. Bountra, S. Bingham, 2009, Bioorganic & medicinal chemistry letters.

Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approach.

A. Naylor, C. Bountra, N. L. Taylor, 2009, Bioorganic & medicinal chemistry letters.

2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.

Andrew J. Brown, P. Beswick, Robert J Gleave, 2009, Bioorganic & medicinal chemistry letters.

A challenge finding P2X1 and P2X4 ligands

M. Lochner, A. J. Thompson, P. Beswick, 2019, Neuropharmacology.